Clinical and Experimental Ophthalmology最新文献

{"title":"Novel Insight of Posterior Capsule Opacification: The Role of Lens Epithelial Cell Senescence","authors":"Yu Ma,&nbsp;Zewen Ren,&nbsp;Yang Chen,&nbsp;Lu Qin,&nbsp;Rong Ju,&nbsp;Yingyan Qin,&nbsp;Mingxing Wu","doi":"10.1111/ceo.14582","DOIUrl":"10.1111/ceo.14582","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Posterior capsule opacification (PCO), the most common complication following cataract surgery, results from the proliferation, migration and epithelial–mesenchymal transition (EMT) of residual lens epithelial cells (LECs), typically driven by postoperative inflammatory and growth factor changes. However, delayed-onset PCO, occurring years after surgery without obvious inflammation, suggests the involvement of additional mechanisms, with senescent cells identified as contributors to EMT. This study investigates the role of LEC senescence in PCO development.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Transcriptomic data from the Gene Expression Omnibus (GEO) were analysed to identify senescence-associated pathways in PCO. Rabbit PCO models and oxidative stress-induced senescent SRA01/04 LECs were treated with dasatinib and quercetin (DQ) to target senescent cells and inhibit the senescence-associated secretory phenotype (SASP). Senescence, SASP and EMT biomarkers were assessed by qPCR, immunofluorescence and Western blotting. Cell migration, proliferation and apoptosis were analysed through wound healing, Transwell and flow cytometry assays.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RNA sequencing from GEO revealed a significant correlation between senescence and PCO. In vitro, oxidative stress-induced senescent LECs exhibited increased EMT biomarkers, including vimentin and α-SMA. In a rabbit PCO model, senescence- and SASP-related genes (p53, MMP3 and IL-6) and proteins were upregulated. DQ treatment reduced senescence and EMT by inhibiting multiple EMT-related signalling pathways, especially the PI3K-Akt pathway (p-PI3K, p-Akt), leading to a significant reduction in PCO volume.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>LEC senescence plays a key role in PCO development. DQ effectively targets multiple EMT signalling pathways, particularly PI3K-Akt, and shows promise as a strategy for the prevention and management of PCO.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 8","pages":"1008-1024"},"PeriodicalIF":5.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal Prostheses for Profound Vision Loss—Have We Lost Our Way?","authors":"Lyndon da Cruz","doi":"10.1111/ceo.14564","DOIUrl":"https://doi.org/10.1111/ceo.14564","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 5","pages":"455-456"},"PeriodicalIF":4.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyaluronic Acid Hydrogel as a Retinal Patch in the Treatment of Rhegmatogenous Retinal Detachment: A Multicenter Randomised Parallel-Controlled Trial","authors":"Boshi Liu,&nbsp;Manqiao Wang,&nbsp;Liangzhang Tan,&nbsp;Emmanuel Eric Pazo,&nbsp;Lili Yuan,&nbsp;Qingli Shang,&nbsp;Jingxue Ma,&nbsp;Jianmin Wang,&nbsp;Xiang Ma,&nbsp;Cong Ma,&nbsp;Qinghuai Liu,&nbsp;Jiangdong Ji,&nbsp;Yao Lu,&nbsp;Yong Tao,&nbsp;Li Chen,&nbsp;Peiquan Zhao,&nbsp;Jiao Lyn,&nbsp;Qiang Lu,&nbsp;Yan Shao,&nbsp;Xinjun Ren,&nbsp;Xiaorong Li","doi":"10.1111/ceo.14570","DOIUrl":"10.1111/ceo.14570","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To evaluate the efficacy and safety of a linearly cross-linked sodium hyaluronic acid (HA) hydrogel used as a retinal patch in the treatment of rhegmatogenous retinal detachment (RRD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicenter, randomised, parallel-controlled trial included 313 participants diagnosed with RRD classified as PVR grade A or B, excluding those with giant retinal tears (defined as tears spanning more than one quadrant). Participants were randomly assigned to either an experimental group or a control group. Following laser photocoagulation to retinal breaks, the experimental group received intraocular tamponade with a combination of linearly cross-linked sodium HA hydrogel and sterile air, whereas the control group received intraocular tamponade with perfluoropropane gas (C3F8). According to the intention-to-treat (ITT) principle, the final analysis included 155 subjects in the experimental group and 158 in the control group. The primary outcome measure was the retinal reattachment rate within 24 weeks postoperatively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At 24 weeks, retinal reattachment rates were 91.8% in the experimental group and 91.4% in the control group (<i>p</i> = 0.903), with no statistically significant differences at any follow-up time point. Additionally, there were no significant differences between the two groups regarding best-corrected visual acuity (BCVA), intraocular pressure (IOP), or postoperative complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The application of linearly cross-linked sodium HA hydrogel as a retinal patch demonstrated effectiveness comparable to traditional gas tamponade in the treatment of RRD. Furthermore, this method exhibited a favourable safety profile. The technique obviates the need for postoperative prone positioning, significantly improving the patient's postoperative comfort and quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Chinese Clinical Trial Registry: ChiCTR2000037030</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 8","pages":"946-955"},"PeriodicalIF":5.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuing Professional Development","authors":"","doi":"10.1111/ceo.14565","DOIUrl":"https://doi.org/10.1111/ceo.14565","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 5","pages":"589-591"},"PeriodicalIF":4.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding Access to Monoclonal Antibody Treatment by the Adoption of Biosimilar Agents","authors":"Michael Goggin","doi":"10.1111/ceo.14553","DOIUrl":"https://doi.org/10.1111/ceo.14553","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 5","pages":"453-454"},"PeriodicalIF":4.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposal of a Simpler Eye-Level Risk Model Incorporating Reticular Pseudodrusen for the Clinical Prediction of Late Age-Related Macular Degeneration","authors":"Matt Trinh,&nbsp;Annita Duong,&nbsp;Rene Cheung,&nbsp;Simon Chen,&nbsp;David Ng,&nbsp;Jeff Friedrich,&nbsp;Chris Hodge,&nbsp;Lisa Nivison-Smith,&nbsp;Angelica Ly","doi":"10.1111/ceo.14576","DOIUrl":"10.1111/ceo.14576","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The updated simplified AREDS risk model predicts progression to late age-related macular degeneration (AMD) by person, describing up to nine observations across both eyes and 10 annual risk scores (0–4, with/without reticular pseudodrusen [RPD]). This study proposes an abridged model to enable inter-eye comparisons and potentially enhance clinical efficiency.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study included 269 participants with early/intermediate AMD over 7 years. The full, person-level updated simplified AREDS risk model was compared to eye-level candidate risk models, derived by removing the least predictive biomarkers. The main outcomes were prognostic performance (AUC) and risk score separability (<i>χ</i>\u0000 ²).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At 1–3 years, the full model showed prognostic performance (AUC ± SE) up to 84.52% ± 5.93%, with overlap between most risk scores (<i>χ</i>\u0000 ² ≤ 2.08). Removing large drusen and pigmentary abnormalities in the fellow eye, intermediate drusen in both eyes, and redefining RPD presence as eye-specific maintained prognostic performance (up to 84.71% ± 4.72%). Assigning one point per retained biomarker, based on similar adjusted risks, improved risk score separability (<i>χ</i>\u0000 ² ≥ 3.85, <i>p</i> &lt; 0.05) while reducing the number of annual scores from 10 to five.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The updated simplified AREDS risk model can be essentially halved without compromising prognostic performance by deriving eye-specific biomarkers and assigning one point per biomarker (large drusen, pigmentary abnormalities, and RPD in the primary eye, and late AMD in the fellow eye). This eye-level risk stratification may improve clinical efficiency and inter-eye study designs when one eye is of particular interest. An example of 3-year risks (scores 0–4) was ≈4%, 8%, 16%, 32%, and 64%.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 8","pages":"936-945"},"PeriodicalIF":5.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ceo.14576","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Pharmaceutical Therapies for Meibomian Gland Dysfunction: From Basic Research to Clinical Practice","authors":"Sai Luo,&nbsp;Yuli Guo,&nbsp;Zuguo Liu","doi":"10.1111/ceo.14577","DOIUrl":"10.1111/ceo.14577","url":null,"abstract":"<div>\u0000 \u0000 <p>Meibomian gland dysfunction (MGD) is a group of chronic abnormalities of meibomian glands (MGs), which is recognised as the leading cause of evaporative dry eye. MGD is characterised by obstruction of the terminal ducts and/or alterations in the glandular secretion, which culminates in alterations in tear film stability, inflammation and ocular irritation. Lately, several physical therapies have been developed clinically, including warming compress and massage, eyelid hygiene, as well as advanced approaches such as intraductal probing, thermal pulsation and intense pulsed light therapy. Recently, there is increasing awareness regarding the pharmaceutical therapies for MGD, which have shown potential. Here, we summarise current pharmaceutical therapies for MGD from four aspects including ameliorating microenvironment, inhibiting keratinisation, regulating secretory function and therapies targeting stem cells based on basic and clinical research, discuss their applications and limitations, and provide perspectives for future studies in the field.</p>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 8","pages":"1039-1055"},"PeriodicalIF":5.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Clinical and Angiographic Outcomes of Ranibizumab and Aflibercept in Type 1 and Aggressive Retinopathy of Prematurity","authors":"Wenting Zhang,&nbsp;Haonan Ma,&nbsp;Jianhui Wang,&nbsp;Zhijun Chen,&nbsp;Xuerui Zhang,&nbsp;Haodong Xiao,&nbsp;Huanyu Liu,&nbsp;Yuan Yang,&nbsp;Jiawei Yin,&nbsp;Mingyang Wang,&nbsp;Jie Peng,&nbsp;Yu Xu,&nbsp;Peiquan Zhao","doi":"10.1111/ceo.14575","DOIUrl":"10.1111/ceo.14575","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To compare the clinical and angiographic outcomes of aggressive retinopathy of prematurity (A-ROP) and type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) or aflibercept (IVA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective, non-randomised study included a consecutive series of patients with type 1 ROP or A-ROP who initially treated with ranibizumab (0.25 mg/0.025 mL) or aflibercept (1.0 mg/0.025 mL) between October 2017 and November 2020. Clinical data and long-term vascular characteristics were analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 297 eyes of 151 infants were included. Compared to IVA, IVR was a significant risk factor for reactivation in multivariate regression analysis. The risk time of reactivation in A-ROP and Type 1 Zone I ROP was shorter in the IVR group (<i>p</i> &lt; 0.001). Fewer injections were required in the IVA group for patients with A-ROP and Type 1 Zone I ROP (<i>p</i> = 0.012). More vascular abnormalities were observed in the IVA group during reactivation, with increased arteriovenous shunting (<i>p</i> = 0.028) in Type 1 Zone II ROP and more tortuosity (<i>p</i> = 0.047), dilation (<i>p</i> = 0.047) and plus disease (<i>p</i> = 0.020) in Type 1 Zone I ROP and A-ROP. In fundus fluorescein angiography, staining of the vessel wall and telangiectasia were more frequent in the IVA group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Ranibizumab treatment was associated with a higher rate of reactivation and a shorter risk period for reactivation compared to aflibercept, potentially requiring more frequent injections, though some differences did not reach statistical significance. However, there were more signs of vascular abnormalities after receiving aflibercept treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 8","pages":"956-966"},"PeriodicalIF":5.6,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ceo.14575","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomised Controlled Trial: Influence of Subconjunctival Anaesthesia Duration on Pain Perception During Intravitreal Injections","authors":"Jiyeon Kim,&nbsp;Louis S. Han,&nbsp;Logan Robinson,&nbsp;Tafadzwa Young-Zvandasara","doi":"10.1111/ceo.14579","DOIUrl":"10.1111/ceo.14579","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The intravitreal injection (IVI) is one of the most performed vitreoretinal procedures in ophthalmology. Subconjunctival anaesthesia (SCA) with 2% lidocaine is a commonly used modality to reduce procedural pain and patient distress. Currently, there is no unifying recommended wait time between SCA and IVI. The purpose of this study is to determine the optimal wait time between the two, whilst maintaining clinical efficiency.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Single-blinded randomised clinical trial. Two hundred and forty patients were randomly assigned to one of four groups: wait time of 2, 3, 4 or 5 min. The primary outcome was pain level graded by the patient on a 10-point visual analogue scale. The secondary outcome was the willingness to receive further IVI with the current pain level. Data points were collected on patient demographics and characteristics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The mean pain scores showed a decreasing trend with increasing wait times, 2.27 (2 min), 1.03 (3 min), 0.67 (4 min) and 0.58 (5 min). More patients were willing to receive further IVI with increasing wait times, 92% (2 min), 97% (3 and 4 min), and 100% (5 min). These differences were statistically significant at each time interval.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Longer wait times post-SCA were associated with better anaesthetic effect and higher patient acceptance to continue receiving IVI. The most marked difference was observed between 2- and 3-min groups. Based on our findings, a minimum wait time of 3 min should be recommended as the group had reported acceptably low pain scores (1.03) while maintaining high patient satisfaction (97%).</p>\u0000 </section>\u0000 </div>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 8","pages":"918-924"},"PeriodicalIF":5.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aqueous Humour Concentration of Topically Applied 2.0% Ganciclovir Eye Drops in Eyes With Cytomegalovirus Anterior Uveitis and Endotheliitis: Comment","authors":"Haixing Cao,&nbsp;Yujie Zhang,&nbsp;Xiang Ma","doi":"10.1111/ceo.14580","DOIUrl":"10.1111/ceo.14580","url":null,"abstract":"","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":"53 8","pages":"1063-1064"},"PeriodicalIF":5.6,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}